These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16413467)

  • 21. The role of scaffold proteins in MEK/ERK signalling.
    Sacks DB
    Biochem Soc Trans; 2006 Nov; 34(Pt 5):833-6. PubMed ID: 17052209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperactive Ras in developmental disorders and cancer.
    Schubbert S; Shannon K; Bollag G
    Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal growth factor receptor is involved in clusterin-induced astrocyte proliferation.
    Shim YJ; Shin YJ; Jeong SY; Kang SW; Kim BM; Park IS; Min BH
    Neuroreport; 2009 Mar; 20(4):435-9. PubMed ID: 19218870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms.
    Cho HJ; Kang JH; Kwak JY; Lee TS; Lee IS; Park NG; Nakajima H; Magae J; Chang YC
    Carcinogenesis; 2007 May; 28(5):1104-10. PubMed ID: 17114644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
    Favre G
    Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Raf/MEK/ERK pathway in pituitary adenomas.
    Suojun Z; Feng W; Dongsheng G; Ting L
    Eur J Cancer; 2012 Feb; 48(3):389-95. PubMed ID: 22119203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway.
    Carie AE; Sebti SM
    Oncogene; 2007 May; 26(26):3777-88. PubMed ID: 17260025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ras/Raf/MEK/ERK cascade].
    Sowa Y; Sakai T
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():63-6. PubMed ID: 23513813
    [No Abstract]   [Full Text] [Related]  

  • 30. Stress kinase signaling in cancer: fact or fiction?
    Rennefahrt U; Janakiraman M; Ollinger R; Troppmair J
    Cancer Lett; 2005 Jan; 217(1):1-9. PubMed ID: 15596290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics.
    Kim DH; Sim T
    Arch Pharm Res; 2012 Mar; 35(4):605-15. PubMed ID: 22553052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. It takes two to tango--signalling by dimeric Raf kinases.
    Baljuls A; Kholodenko BN; Kolch W
    Mol Biosyst; 2013 Apr; 9(4):551-8. PubMed ID: 23212737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts.
    Galabova-Kovacs G; Kolbus A; Matzen D; Meissl K; Piazzolla D; Rubiolo C; Steinitz K; Baccarini M
    Cell Cycle; 2006 Jul; 5(14):1514-8. PubMed ID: 16861903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targets of Raf in tumorigenesis.
    Niault TS; Baccarini M
    Carcinogenesis; 2010 Jul; 31(7):1165-74. PubMed ID: 20047953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Signaling through RAS-RAF-MEK-ERK: from basics to bedside.
    Zebisch A; Czernilofsky AP; Keri G; Smigelskaite J; Sill H; Troppmair J
    Curr Med Chem; 2007; 14(5):601-23. PubMed ID: 17346150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Ras/Raf/MAPK pathway.
    Molina JR; Adjei AA
    J Thorac Oncol; 2006 Jan; 1(1):7-9. PubMed ID: 17409820
    [No Abstract]   [Full Text] [Related]  

  • 37. Development of small-molecule inhibitors of Raf.
    Wu S; Guo W; Fang B
    Recent Pat Antiinfect Drug Discov; 2006 Jun; 1(2):241-6. PubMed ID: 18221149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raf kinases: function, regulation and role in human cancer.
    Leicht DT; Balan V; Kaplun A; Singh-Gupta V; Kaplun L; Dobson M; Tzivion G
    Biochim Biophys Acta; 2007 Aug; 1773(8):1196-212. PubMed ID: 17555829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the Raf kinases in human cancer: the Raf dimer dilemma.
    Durrant DE; Morrison DK
    Br J Cancer; 2018 Jan; 118(1):3-8. PubMed ID: 29235562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Back to the roots: the remarkable RAF oncogene story.
    Zebisch A; Troppmair J
    Cell Mol Life Sci; 2006 Jun; 63(11):1314-30. PubMed ID: 16649144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.